Summary of Takeda's Q2 FY 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: JPY 2.2 trillion, down 6.9% YoY (down 3.9% at constant exchange rates).

Core Operating Profit: JPY 639.2 billion, a decline of 11.2% YoY (8.8% at CER).

Reported Operating Profit: JPY 253.6 billion, down 27.7% YoY due to higher impairment losses.

Core EPS: JPY 279; Reported EPS: JPY 72, reflecting a 40% decline in net profit due to a non-deductible impairment loss.

Free Cash Flow: Strong at JPY 525.4 billion, aided by improved working capital.

2Strategic Updates and Business Highlights

Product Growth: Launch products grew 5.3% at CER, with expectations for acceleration in H2.

ENTYVIO: Growth slowed; revised full-year forecast to 6% at CER due to competitive pressures and slower pen conversion.

Oncology Pipeline: Positive Phase III results for rusfertide and oveporexton; partnership with Innovent Biologics to enhance oncology portfolio with three new assets.

Operational Efficiency: Continued focus on cost control and operational efficiencies, including a restructuring plan impacting 600 positions.

3Forward Guidance and Outlook

Updated Guidance: Total revenue expected to remain broadly flat YoY; core operating profit and EPS guidance revised to low single-digit percentage declines due to transactional FX impacts.

Dividend Outlook: Maintained at JPY 200 per share for the full year.

Future Growth: Anticipation of a new business cycle post-VYVANSE generic impact, with potential new product launches and pipeline advancements.

4Bad News, Challenges, or Points of Concern

VYVANSE Impact: Significant revenue loss (approx. JPY 100 billion) due to loss of exclusivity, with expectations of continued decline.

Transactional FX Headwinds: Euro appreciation negatively impacting profits and product costs, particularly for QDENGA.

Competitive Pressures: Increased competition affecting ENTYVIO growth, particularly in Crohn's disease (CD) and challenges in expanding access to the ENTYVIO Pen.

Impairment Losses: Higher impairment losses from discontinued cell therapy efforts affecting reported profits.

5Notable Q&A Insights

ENTYVIO Access: Ongoing efforts to improve insurance coverage and local market access, with expectations for growth acceleration as hurdles are resolved.

Innovent Partnership Concerns: Questions raised about R&D costs and the ability to replicate positive data from China in international trials; Takeda remains confident in their due diligence.

Celiac Disease Programs: Takeda is optimistic about ongoing Phase II studies, with potential for significant market impact if successful.

PDT Business: Focus on improving efficiency rather than expanding collection centers; confident in achieving high single-digit growth for albumin despite market challenges in China. Overall, Takeda's Q2 FY 2025 results reflect a challenging environment primarily due to the impact of VYVANSE generics and currency fluctuations, but the company is strategically positioned for future growth through pipeline advancements and operational efficiencies.